Real-world evidence helps pharmaceutical companies and payers communicate more effectively. In this Q&A, Cate Lockhart, PharmD, PhD, chief science officer of the Academy of Managed Care Pharmacy (AMCP ...

Across conversations on precision oncology, malignant hematology, cellular therapies, and social determinants of health (SDOH ...

Equitable access to genomic testing for NSCLC patients is vital for advanced therapy access, with strategies including commercial contracts and financial assistance programs. Financial toxicity and ...

Metabolic reprogramming in fibrotic lung diseases involves key metabolites like lactate, succinate, and 2-hydroxyglutarate, ...

Marc S. Raab, MD, PhD, discusses the different ways that combination therapy that includes teclistamab can benefit patients ...

Neoadjuvant immunochemotherapy shows higher pCR and MPR rates compared to chemotherapy alone in LS-SCLC patients, suggesting enhanced tumor regression before surgery. Propensity score matching ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for major cardiovascular events and for all-cause mortality, according to a new analysis of real-world ...

Value-based oncology care requires balancing rapid innovation with operational sustainability, equitable access, and ...

Amid rapid advances in oncology, barriers such as treatment costs, health inequities, and clinician burnout remain critical challenges, as highlighted by experts at a regional Institute for ...

1. Garg S, Donnenfeld E, Sheppard J, Epitropoulos A, Brady TC. Reproxalap improves ocular redness, tear production, and ...

Panelists discuss how real-world outcomes inform patient conversations and support shared decision-making for third-line ...

Panelists explain that in the absence of head-to-head trial data, real-world evidence (RWE) becomes crucial in guiding ...